Amedisys (NASDAQ:AMED) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Amedisys (NASDAQ:AMED) issued its quarterly earnings results on Wednesday. The health services provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01, Briefing.com reports. The business had revenue of $571.41 million for the quarter, compared to the consensus estimate of $565.38 million. Amedisys had a negative net margin of 0.44% and a positive return on equity of 12.76%. The firm’s quarterly revenue was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.00 EPS.

Amedisys Trading Up 0.1 %

Shares of NASDAQ AMED traded up $0.08 during midday trading on Thursday, reaching $91.13. 62,433 shares of the stock were exchanged, compared to its average volume of 275,624. The business has a 50-day simple moving average of $92.63 and a two-hundred day simple moving average of $93.37. The company has a market capitalization of $2.98 billion, a price-to-earnings ratio of -292.96, a P/E/G ratio of 4.29 and a beta of 0.86. Amedisys has a 12 month low of $73.10 and a 12 month high of $96.44. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.05 and a quick ratio of 1.05.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Royal Bank of Canada upped their price target on shares of Amedisys from $97.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, March 25th. Raymond James reissued a “market perform” rating on shares of Amedisys in a report on Tuesday, March 26th. StockNews.com initiated coverage on Amedisys in a report on Monday, April 8th. They set a “buy” rating for the company. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $101.00 price objective on shares of Amedisys in a report on Thursday. Seven research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $97.50.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.